Immutep (ASX:IMM) reports first subject dosed in autoimmune disease study
19 Aug 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses progress with the company's IMP761 drug, which is potentially active in more than 90% of autoimmune diseases.